Sales & Marketing News | pharmaphorum

News

AstraZeneca plans new US R&D hub as revenues rocket

AstraZeneca has revealed plans to set up a new strategic R&D hub in Cambridge, Massachusetts as it reported a massive increase in first-quarter revenues, driven by COVID-19 and oncology

News

Pfizer/Biohaven migraine drug rimegepant gets EU green light

Pfizer's $1.2 billion licensing deal with Biohaven for rights to oral migraine drug rimegepant is approaching a payoff after the European Commission approved the drug.

News

Merck makes $3.2bn from COVID-19 drug Lagevrio in Q1

Orders for Merck & Co's oral antiviral for COVID-19 helped to swell the drugmaker's first quarter revenues by a massive 50%, although underlying growth was also strong.

News

GSK beats forecasts, thanks to COVID antibody and Shingrix s...

GlaxoSmithKline has made a promising start to 2022 with a 32% rise in group sales, albeit measured against a downbeat first-quarter result in 2021.

News

GSK workers vote for strike action over "derisory" pay offer

Workers at a number of GlaxoSmithKline manufacturing plants in the UK have voted to take industrial action over what the Unite union has described as a "derisory" pay offer.

News

Pills spilling out of a prescription bottle on 100 dollar paper currency

US meds spending spiked last year, but will fall quickly

Prescription drug use in the US soared last year, as might be expected during a pandemic, but is expected to fall back sharply in 2023, according to IQVIA's latest report on the sector.

AstraZeneca plans new US R&D hub as revenues rocket

Pfizer/Biohaven migraine drug rimegepant gets EU green light

Merck makes $3.2bn from COVID-19 drug Lagevrio in Q1

GSK beats forecasts, thanks to COVID antibody and Shingrix s...

GSK workers vote for strike action over "derisory" pay offer

US meds spending spiked last year, but will fall quickly

Trustworthy and novel AI in clinical trial planning, with Kr...

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks